Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Wei Zhen Yeh,Putu Ayu Widyastuti,Anneke Van der Walt,Jim Stankovich,Eva Havrdova,Dana Horakova,Karolina Vodehnalova,Serkan Ozakbas,Sara Eichau,Pierre Duquette,Tomas Kalincik,Francesco Patti,Cavit Boz,Murat Terzi,Bassem I Yamout,Jeannette Lechner-Scott,Patrizia Sola,Olga G Skibina,Michael Barnett,Marco Onofrj,Maria José Sá,Pamela Ann McCombe,Pierre Grammond,Radek Ampapa,Francois Grand'Maison,Roberto Bergamaschi,Daniele L A Spitaleri,Vincent Van Pesch,Elisabetta Cartechini,Suzanne Hodgkinson,Aysun Soysal,Albert Saiz,Melissa Gresle,Tomas Uher,Davide Maimone,Recai Turkoglu,Raymond Mm Hupperts,Maria Pia Amato,Franco Granella,Celia Oreja-Guevara,Ayse Altintas,Richard A Macdonell,Tamara Castillo-Trivino,Helmut Butzkueven,Raed Alroughani,Vilija G Jokubaitis,Bassem I. Yamout,Olga G. Skibina,Daniele L.A. Spitaleri,Raymond M.M. Hupperts,Richard A. Macdonell,Vilija G. Jokubaitis,
DOI: https://doi.org/10.1212/wnl.0000000000012084
IF: 9.9
2021-04-20
Neurology
Abstract:Objective To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort. Methods Using data from the MSBase Registry, we included pregnancies conceived after December 31, 2010, in women with relapsing-remitting MS or clinically isolated syndrome. Predictors of intrapartum relapse and postpartum relapse and disability progression were determined by clustered logistic regression or Cox regression analyses. Results We included 1,998 pregnancies from 1,619 women with MS. Preconception annualized relapse rate (ARR) was 0.29 (95% confidence interval 0.27–0.32), fell to 0.19 (0.14–0.24) in the third trimester, and increased to 0.59 (0.51–0.67) in early postpartum. Among women who used fingolimod or natalizumab, ARR before pregnancy was 0.37 (0.28–0.49) and 0.29 (0.22–0.37), respectively, and increased during pregnancy. Intrapartum ARR decreased with preconception dimethyl fumarate use. ARR spiked after delivery across all DMT groups. Natalizumab continuation into pregnancy reduced the odds of relapse during pregnancy (odds ratio 0.76 per month [0.60–0.95], p = 0.017). DMT reinitiation with natalizumab protected against postpartum relapse (hazard ratio [HR] 0.11 [0.04–0.32], p < 0.0001). Breastfeeding women were less likely to relapse (HR 0.61 [0.41–0.91], p = 0.016). We found that 5.6% of pregnancies were followed by confirmed disability progression, predicted by higher relapse activity in pregnancy and postpartum. Conclusion Intrapartum and postpartum relapse probabilities increased among women with MS after natalizumab or fingolimod cessation. In women considered to be at high relapse risk, use of natalizumab before pregnancy and continued up to 34 weeks gestation with early reinitiation after delivery is an effective option to minimize relapse risks. Strategies of disease-modifying therapy use have to be balanced against potential fetal/neonatal complications.
clinical neurology